These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21036708)

  • 41. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
    Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
    Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
    Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
    Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
    Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
    Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
    Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
    Furtado M; Johnson R; Kruger A; Turner D; Rule S
    Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mantle cell lymphoma activation enhances bortezomib sensitivity.
    Brennan SK; Meade B; Wang Q; Merchant AA; Kowalski J; Matsui W
    Blood; 2010 Nov; 116(20):4185-91. PubMed ID: 20570863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    Orciuolo E; Buda G; Pelosini M; Petrini M
    Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
    [No Abstract]   [Full Text] [Related]  

  • 49. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
    Guo Q; Chen Y; Wu Y
    Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
    Camara-Clayette V; Koscielny S; Roux S; Lamy T; Bosq J; Bernard M; Fest T; Lazar V; Lenoir G; Ribrag V
    PLoS One; 2013; 8(9):e73993. PubMed ID: 24069261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
    Kamat AM; Karashima T; Davis DW; Lashinger L; Bar-Eli M; Millikan R; Shen Y; Dinney CP; McConkey DJ
    Mol Cancer Ther; 2004 Mar; 3(3):279-90. PubMed ID: 15026548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
    Falchook GS; Duvic M; Hong DS; Wheler J; Naing A; Lim J; Kurzrock R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1117-26. PubMed ID: 22205203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
    Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
    BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
    Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
    Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
    Bibas M; Grisetti S; Alba L; Picchi G; Del Nonno F; Antinori A
    J Clin Oncol; 2010 Dec; 28(34):e704-8. PubMed ID: 20823416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.